Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07523763) titled 'Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer' on April 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Blokhin's Russian Cancer Research Center
Condition:
Colorectal Cancer (MSI-H)
Colorectal Cancer (CRC)
Intervention:
Drug: Nivolumab or pembrolizumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 22, 2024
Target Sample Size: 30
Countries of Recruitment:
Russia
To know more, visit https://clinica...